Arcturus Therapeutics Holdings (ARCT) FCF Margin (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted FCF Margin of 943.28% for Q1 2026, down 320.59% on a QoQ basis from 224.28% in Q4 2025, and down 82322.0% year-over-year from N/an in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) FCF Margin (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' FCF Margin history runs 9 years deep, the most recent figure standing at 943.28% for Q1 2026.
- Quarterly FCF Margin fell 82322.0% year-over-year to 943.28% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 107.23% (down 4468.0% YoY) and the FY2025 annual result came in at 90.82%, down 5117.0% from the prior year.
- FCF Margin was 943.28% for Q1 2026 at Arcturus Therapeutics Holdings, down from 224.28% in the prior quarter.
- Across five years, FCF Margin topped out at 478.53% in Q2 2023 and bottomed at 975.4% in Q1 2022.
- A 5-year average of 148.9% and a median of 61.11% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin surged 153201 bps — and 2026, when it tumbled 82322 bps.
- Arcturus Therapeutics Holdings' FCF Margin stood at 102.07% in 2022, then slumped by 105 bps to 4.87% in 2023, then jumped by 74 bps to 1.25% in 2024, then slumped by 17879 bps to 224.28% in 2025, then tumbled by 321 bps to 943.28% in 2026.
- Business Quant data shows ARCT's FCF Margin at 943.28% in Q1 2026, 224.28% in Q4 2025, and 101.06% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | -943.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -943.28% |
| Dec 31, 2025 | -224.28% |
| Sep 30, 2025 | -101.06% |
| Jun 30, 2025 | -20.33% |
| Mar 31, 2025 | -120.06% |
| Dec 31, 2024 | -1.25% |
| Sep 30, 2024 | -57.22% |
| Jun 30, 2024 | -61.11% |
| Mar 31, 2024 | -15.25% |
| Dec 31, 2023 | -4.87% |
| Sep 30, 2023 | -75.00% |
| Jun 30, 2023 | 478.53% |
| Mar 31, 2023 | -44.81% |
| Dec 31, 2022 | 102.07% |
| Sep 30, 2022 | -333.55% |
| Jun 30, 2022 | -134.51% |
| Mar 31, 2022 | -975.40% |
| Dec 31, 2021 | -733.34% |
| Sep 30, 2021 | -664.38% |
| Jun 30, 2021 | -1,666.52% |